AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation

Tools

AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation

NEKTAR THERAPEUTICS CONTACTS  
 
Nektar Investor Inquiries  
Jennifer Ruddock/Nektar Therapeutics 415-482-5585
Susan Noonan/SA Noonan Communications, LLC 212-966-3650
 
Nektar Media Inquiries  
Mary Cunney/MSL 917-208-2162
Mike Huckman/MSL 646-500-7631         
 
ASTRAZENECA CONTACTS  
 
Media Enquiries UK  
Esra Erkal-Paler +44 20 7604 8030
Vanessa Rhodes +44 20 7604 8037
 
Media  Enquiries Sweden   
Ann-Leena Mikiver +46 8 553 260 20
 
Investor Enquiries    
James Ward-Lilley +44 20 7604 8122  mob: +44 7785 432613
Karl Hard +44 20 7604 8123 mob: +44 7789 654364
Nicklas Westerholm +44 20 7604 8124  mob: +44 7585 404950
Ed Seage +1 302 886 4065    mob: +1 302 373 1361

SOURCE Nektar Therapeutics


Read more here: http://www.sacbee.com/2012/11/12/4978657/astrazeneca-announces-top-line.html#storylink=cpy